A Meta-analysis of the NAT1 and NAT2 Polymorphisms and Prostate Cancer: a Huge Review

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2010 Jan 26

PMID 20099048

Citations 12

Authors

Chunming Gong

Xueying Hu

Yong Gao

Yunfei Cao

Feng Gao

Zengnan Mo

Affiliations

Soon will be listed here.

Abstract

Studies revealing conflicting results on the role of NAT1 or NAT2 phenotypes on prostate cancer risk led us to perform a meta-analysis to investigate the association of these polymorphisms and prostate cancer risk. The meta-analysis included six studies with NAT1 genotyping (610 prostate cancer cases and 713 controls), and 10 studies with NAT2 genotyping (1,253 cases and 1,722 controls). The fixed effects odds ratio was 0.96 [95% confidence interval (95% CI): 0.75, 1.21; I(2) = 32.9%, P for heterogeneity = 0.189] for the NAT1 genotype, and the random effects odds ratio was 1.10 (95% CI: 0.87, 1.39; I(2) = 49.1%, P for heterogeneity = 0.039) for the NAT2 genotype. For NAT2 polymorphism, a statistically significant association between NAT2 polymorphism and prostate cancer appeared in Asians, but not in Caucasians. In conclusion, the NAT1 or NAT2 phenotypes detoxify carcinogens and their reactive intermediates are unlikely to be the cause of PCa development.

Citing Articles

Downregulation of NAT1 Expression is Associated with Poor Prognosis and Immune Infiltration in COAD.

Xu H, Zhang H, Sun S, Zhang J, Huo J, Zhou C Pharmgenomics Pers Med. 2024; 17:133-148.

PMID: 38651072 PMC: 11033211. DOI: 10.2147/PGPM.S455490.

Evaluation of Genetic Polymorphisms of N-acetyltransferase 2 and Relation with Chronic Myeloid Leukemia.

Tebien E, Khalil H, Mills J, Elderdery A Asian Pac J Cancer Prev. 2020; 21(12):3711-3717.

PMID: 33369472 PMC: 8046315. DOI: 10.31557/APJCP.2020.21.12.3711.

Association between NAT2, CYP1A1, and CYP1A2 genotypes, heterocyclic aromatic amines, and prostate cancer risk: a case control study in Japan.

Koda M, Iwasaki M, Yamano Y, Lu X, Katoh T Environ Health Prev Med. 2017; 22(1):72.

PMID: 29165164 PMC: 5664586. DOI: 10.1186/s12199-017-0681-0.

Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism.

Stepp M, Doll M, Samuelson D, Sanders M, States J, Hein D BMC Cancer. 2017; 17(1):233.

PMID: 28359264 PMC: 5374573. DOI: 10.1186/s12885-017-3221-9.

NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.

Zhang K, Gao L, Wu Y, Chen J, Lin C, Liang S Int J Clin Exp Med. 2015; 8(6):9177-91.

PMID: 26309576 PMC: 4537954.

References

Slager S, Zarfas K, Brown W, Lange E, McDonnell S, Wojno K . Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate. 2005; 66(2):173-9. DOI: 10.1002/pros.20332. View

Reszka E, Wasowicz W . Genetic polymorphism of N-acetyltransferase and glutathione S-transferase related to neoplasm of genitourinary system. Minireview. Neoplasma. 2002; 49(4):209-16. View

Wang C, Jones R, Debiec-Rychter M, Soos G, Haas G . Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study. Anticancer Res. 2003; 22(6B):3529-35. View

Lin H, Probst-Hensch N, Hughes N, Sakamoto G, Louie A, Kau I . Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics. 1998; 8(3):269-81. DOI: 10.1097/00008571-199806000-00009. View

Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C . Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999; 28(1):1-9. DOI: 10.1093/ije/28.1.1. View

Agundez J, Martinez C, Olivera M, Gallardo L, Ladero J, Rosado C . Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. Br J Cancer. 1998; 78(10):1361-7. PMC: 2063181. DOI: 10.1038/bjc.1998.685. View

Yin M, Bastacky S, Chandran U, Becich M, Dhir R . Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol. 2008; 179(3):892-5. DOI: 10.1016/j.juro.2007.10.057. View

Wadelius M, Autrup J, Stubbins M, Andersson S, Johansson J, Wadelius C . Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics. 1999; 9(3):333-40. DOI: 10.1097/00008571-199906000-00008. View

Ebisawa T, Deguchi T . Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun. 1991; 177(3):1252-7. DOI: 10.1016/0006-291x(91)90676-x. View

10.

Boyle P, Severi G, Giles G . The epidemiology of prostate cancer. Urol Clin North Am. 2003; 30(2):209-17. DOI: 10.1016/s0094-0143(02)00181-7. View

11.

Blum M, Demierre A, Grant D, Heim M, Meyer U . Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A. 1991; 88(12):5237-41. PMC: 51847. DOI: 10.1073/pnas.88.12.5237. View

12.

Kinoshita Y, Singh A, Rovito Jr P, Wang C, Haas G . Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer. 2004; 3(2):83-6. DOI: 10.3816/cgc.2004.n.016. View

13.

Lo-Guidice J, Allorge D, Chevalier D, Debuysere H, Fazio F, Lafitte L . Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay. Pharmacogenetics. 2000; 10(4):293-300. DOI: 10.1097/00008571-200006000-00003. View

14.

Zhao B, Lee E, Yeoh P, Gong N . Detection of mutations and polymorphism of N-acetyltransferase 1 gene in Indian, Malay and Chinese populations. Pharmacogenetics. 1998; 8(4):299-304. DOI: 10.1097/00008571-199808000-00003. View

15.

Stanford J, FitzGerald L, McDonnell S, Carlson E, McIntosh L, Deutsch K . Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet. 2009; 18(10):1839-48. PMC: 2671990. DOI: 10.1093/hmg/ddp100. View

16.

Fukutome K, Watanabe M, Shiraishi T, Murata M, Uemura H, Kubota Y . N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development. Cancer Lett. 1999; 136(1):83-7. DOI: 10.1016/s0304-3835(98)00311-5. View

17.

Sekine A, Saito S, Iida A, Mitsunobu Y, Higuchi S, Harigae S . Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population. J Hum Genet. 2001; 46(6):314-9. DOI: 10.1007/s100380170065. View

18.

Hamasaki T, Inatomi H, Katoh T, Aono H, Ikuyama T, Muratani T . N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol. 2003; 10(3):167-73. DOI: 10.1046/j.1442-2042.2003.00586.x. View

19.

Smelt V, Upton A, Adjaye J, Payton M, Boukouvala S, Johnson N . Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum Mol Genet. 2000; 9(7):1101-7. DOI: 10.1093/hmg/9.7.1101. View

20.

Gudmundsson J, Sulem P, Manolescu A, Amundadottir L, Gudbjartsson D, Helgason A . Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007; 39(5):631-7. DOI: 10.1038/ng1999. View